Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Calliditas

Biotech & Life Sciences · Stockholm, Sweden · Founded 1992 · IPO 2018 Unicorn

Pharmaceutical company developing high value products for patients with significant unmet medical needs

Valuation
$1.05B
Market cap · 2026
Revenue
$420M
Latest reported FY
EBITDA
$447M
Latest reported FY

Investors

1 investor on Calliditas's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 1 investor entered at this stage

Global footprint

Where Calliditas has talent and traffic

Workforce by country
6 countries with
team presence
🇺🇸 United States65.5%
🇸🇪 Sweden24.8%
🇫🇷 France4.1%
🇨🇭 Switzerland3.6%
🇬🇧 United Kingdom1.8%
Top 5 of 6 shown
Web traffic by country
3.4K monthly visits
across markets
🇺🇸 United States85.3%
🇮🇳 India14.7%
Top 2 markets shown

Patent intelligence

$13M patent portfolio · 10 active families

Estimated portfolio value
$13M
1.2% of market cap · 41.7× smaller than top peer ChemoCentryx ($524M)
10 active patent families
Where Calliditas innovates DrugPharmaceutical drugOrganic chemistryBudesonideGastrointestinal tract

Where Calliditas concentrates vs peers

Each axis is a top-10 topic across Calliditas and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Calliditas

An AI-synthesized read of the highest-engagement posts about Calliditas on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Calliditas on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.